Abstract
Background: Prolactinoma is an estrogen-related tumor, and some anti-estrogen agents have suppressive effects on prolactinoma. Previous studies have suggested that fulvestrant, a selective estrogen receptor antagonist, has /INS;inhibitory effects on the proliferation and prolactin secretion of MMQ and GH3 cells in vitro. However, there is still limited evidence of the inhibitory effects of fulvestrant on prolactinoma in vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
